

Clinical trial summary (S2408)

Lanreotide versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula



What is the purpose of this clinical trial?

This trial is for people who will have a type of surgery called a **distal pancreatectomy**. This surgery removes part of the pancreas to treat pancreatic tumors.

The goal of this study is to learn if giving people a medicine called **lanreotide** before surgery can help prevent a complication called a **pancreatic fistula** after surgery. A pancreatic fistula happens when the pancreas has a small leak, which can cause serious problems.

Most people having this surgery don't receive any medicine to prevent pancreatic fistulas.

This trial is set up to find out if giving patients lanreotide before the surgery can:

- Help prevent pancreatic fistulas
- Lead to shorter hospital stays
- Help improve quality of life



Why is this trial important?

Pancreatic fistulas can lead to other serious problems and may cause delays in other cancer treatments that patients need. This trial will help researchers find out if it's possible to lower people's risk of pancreatic fistulas so they have an easier recovery and better quality of life after surgery.



Who can be in this trial?

This trial is for adults age 18 or older.

This trial is for people who:

- Have pancreatic cancer or a growth on the pancreas
- Will have surgery to remove part of the pancreas

This trial is not for people who:

- Have malabsorption syndrome
- Were treated with radiation or peptide receptor radionuclide therapy (PRRT)
- Were treated with a somatostatin analogue (like lanreotide or octreotide) in the last 6 months
- Are pregnant or breastfeeding — or may become pregnant within 6 months after surgery



What treatments will I get?

A computer will randomly assign you to one of 2 study groups.

Group 1: lanreotide

1 injection (shot) of lanreotide shortly before surgery

Group 2: placebo

1 injection (shot) of placebo shortly before surgery

A **placebo** is something that looks like the study drug but contains no medicine. The placebo in this study is a mix of salt and water.

You won't know whether you get lanreotide or a placebo — and your doctor won't know either. This helps make sure the study results are fair and reliable.



How long will I be in the trial?

Most of the study will take place within **2 months** of your surgery. During this time, you'll fill out a few short surveys about your quality of life. The study team may check in with you for **up to 1 year** after your surgery to see how you're doing.



Are there costs? Will I get paid?

You won't need to pay for the lanreotide or placebo you'll receive in the study. To learn more about what costs will and won't be covered, talk with your health care provider and insurance provider.

You will not be paid for joining the study.



Where can I find more information about this trial?

- Talk with your health care provider
- Call the National Cancer Institute at **1-800-4-CANCER**
- Go to www.ClinicalTrials.gov and search the national clinical trial number: **NCT06807437**
- For a list of trial locations, visit swog.org/NCI-S2408



Key information This trial is for adults 18 years or older being

Protocol number: S2408

NCT number: NCT06807437

Full trial title: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Trial sponsor: SWOG Cancer Research Network

Publishing date: March 17, 2025

Thank you!

When you join a clinical trial, you're moving cancer medicine and patient care forward.